NEW YORK— LinusBio, a pioneer in precision exposome sequencing, said that it had secured more than USD 16 million in Series A investment to develop a revolutionary platform that connects genetics, the environment, and biological response.
Many medical disorders, including autism spectrum disorder, have historically lacked biological testing to help diagnose, track development, or act as objective endpoints in clinical trials. LinusBio’s patented technology delivers precise exposome biomarkers, which can help with discovery in various fields.
The technique has the potential to profoundly change how complicated illnesses such as autism, gastrointestinal problems, amyotrophic lateral sclerosis (ALS), and renal failure are identified and treated.
Furthermore, by giving data equivalent to over 500 liquid biopsies or blood samples from a single strand of hair, the LinusBio platform can significantly improve clinical studies. It is the first technological platform to map the molecular dynamics of human physiology in real-time. The technology can aid in discovering new drugs for diseases where genetic biomarkers have previously had little success. This technology is already being used in two pharma-sponsored studies, and the business is in the process of working with other organizations in the healthcare and pharma ecosystem.
The first emphasis of the firm is on neurological problems. StrandDxTM-ASD, one of the company’s early technologies, can predict the possibility of autism at birth with 80% to 90% accuracy and help with individualized therapy.
LinusBio’s early autism diagnostic assistance has been given FDA Breakthrough Designation, designated for discoveries that “allow for more effective treatment or diagnosis of life-threatening or permanently debilitating illnesses or disorders.” The solution has been CE Marked as a diagnostic aid in the European Union.
For people on the autistic spectrum, early identification is essential. The National Institutes of Health discovered that some children detected and treated early make significant progress.
LinusBio’s technology investigates human physiology at the molecular level using a strand of hair. LinusBio analyzes these strands and gathers millions of data points using patented laser and robotics technologies to assess people’s biological responses to their lifetime environmental exposures. LinusBio is the first technology platform to record the molecular dynamics of human physiology throughout time.
The funds will expand the LinusBio team, provide more positive outcomes across a broader range of health issues, and create a world-class platform that will act as a central point for diagnosis and therapy.
We try our best to fact-check and bring the best, well-researched, and non-plagiarized content to you. Please let us know
-if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!
Next Article
